Article

EGF receptor activation during allergic sensitization affects IL-6-induced T-cell influx to airways in a rat model of asthma.

Meakins-Christie Laboratories, McGill University, Montreal, QC, Canada.
European Journal of Immunology (impact factor: 5.1). 04/2010; 40(6):1590-602. DOI:10.1002/eji.200939907 pp.1590-602
Source: PubMed

ABSTRACT EGF receptor (EGFR) is involved in cell differentiation and proliferation in airways and may trigger cytokine production by T cells. We hypothesized that EGFR inhibition at the time of allergic sensitization may affect subsequent immune reactions. Brown Norway rats were sensitized with OVA, received the EGFR tyrosine kinase inhibitor, AG1478 from days 0 to 7 and OVA challenge on day 14. OVA-specific IgE in serum and cytokines and chemokines in BAL were measured 24 h after challenge. To evaluate effects on airway hyperresponsiveness (AHR), rats were sensitized, treated with AG1478, intranasally challenged, and then AHR was assessed. Furthermore chemotactic activity of BALF for CD4(+) T cells was examined. The eosinophils, neutrophils and lymphocytes in BAL were increased by OVA and only the lymphocytes were reduced by AG1478. OVA significantly enhanced IL-6 concentration in BAL, which was inhibited by AG1478. However AHR, OVA-specific IgE and IL-4 mRNA expression in CD4(+) T cells were not affected by AG1478. BALF from OVA-sensitized/challenged rats induced CD4(+) T-cell migration, which was inhibited by both AG1478 treatment in vivo and neutralization of IL-6 in vitro. EGFR activation during sensitization may affect the subsequent influx of CD4(+) T cells to airways, mainly mediated through IL-6.

0 0
 · 
0 Bookmarks
 · 
45 Views
  • Source
    Article: Treatment with a sphingosine-1-phosphate analog inhibits airway remodeling following repeated allergen exposure
    Harry Karmouty-Quintana, Sana Siddiqui, Muhannad Hassan, Kimitake Tsuchiya, Paul-Andre Risse, Laura Xicota-Vila, Maria Marti-Solano, James G. Martin
    [show abstract] [hide abstract]
    ABSTRACT: Treatment with a sphingosine-1-phosphate analog inhibits airway remodeling following repeated allergen exposure. Am J Physiol Lung Cell Mol Physiol 302: L736–L745, 2012. First published January 27, 2012; doi:10.1152/ajplung.00050.2011.—Sphingosine-1-phosphate (S1P) is an immunomodulatory lipid mediator that plays an important role in lymphocyte trafficking. Elevated levels of S1P are found in bronchoalveolar lavage (BAL) fluid of patients with asthma; however, its role in disease is not known. FTY720, a synthetic analog of S1P, has been shown to abrogate allergic inflammation and airway hyperresponsiveness following acute allergen challenge. However, its effects on asthmatic airway remodeling induced by repeated allergen exposure are unknown. Ovalbumin (OVA)-sensitized rats were challenged on days 14, 19, and 24 after sensitization. FTY720 or vehicle (PBS) therapy was administered 1 h prior to each challenge. BAL fluid and quantitative histological analysis were performed 48 h after the last challenge. FTY720 inhibited OVA-induced features of airway remodeling including increased airway smooth muscle mass and bronchial neovascularization, without affecting lymphocyte numbers in secondary lymphoid organs. Furthermore, CD3� cells adjacent to airway smooth muscle bundles were increased in OVA-challenged rats but the increase was inhibited by FTY720. There was an expansion of bronchus-associated lymphoid tissue following FTY720 treatment of OVA-challenged animals. Real-time quantitative PCR revealed that Th2-associated transcription factors were inhibited following FTY720 therapy. Airway remodeling is a cardinal feature of severe asthma. These results demonstrate that allergen-driven airway remodeling can be inhibited by FTY720, offering potential new therapies for the treatment of severe asthma.
    AJP Lung Cellular and Molecular Physiology 01/2012; 302:L736-L745. · 3.66 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

allergic sensitization
 
Brown Norway rats
 
chemotactic activity
 
cytokine production
 
cytokines
 
EGF receptor
 
EGFR activation
 
EGFR inhibition
 
EGFR tyrosine kinase inhibitor
 
IL-4 mRNA expression
 
intranasally
 
neutrophils
 
OVA-sensitized/challenged rats induced CD4(+)
 
OVA-specific IgE
 
proliferation
 
sensitization
 
subsequent immune reactions
 
subsequent influx
 
T cells
 
vitro